Journal Club: 2024.04.26

Vitexin inhibits pain and itch behavior via modulating TRPV4 activity in mice

Zhiqiang Qin ^a1, Lan Xiang ^a1, Siyu Zheng ^a1, Yuchen Zhao ^b, Yanyan Qin ^a, Lei Zhang ^a, Lanlan Zhou ^a

^aSchool of Medical Technology and Nursing, Shenzhen Polytechnic, Shenzhen 518055, China ^bDepartment of Mathematics, University of California, Los Angeles, CA 90095, USA Received 6 March 2023, Revised 27 June 2023, Accepted 28 June 2023, Available online 3 July 2023, Version of Record 3 July 2023.

https://doi.org/10.1016/j.biopha.2023.115101

Abstract
Itching and pain are distinct unpleasant sensations. The transient receptor potential cation channel subfamily V member 4 (TRPV4) pathway is regarded as a shared pathway that mediates pain and itching. Vitexin (Mujingsu, MJS), a C-glycosylflavonoid, is an effective analgesic. This study aimed to explore the antinociceptive and anti-pruritic effects of MJS and whether its effects are mediated via the TRPV4 pathway. Mice were treated with MJS (7.5 mg/kg) 0.5 h prior to the initiation of the pain or itch modeling process. The results showed that MJS suppressed pain-like behavior in hot plate, thermal infiltration, glacial acetic acid twisting, and formalin tests. Administration of MJS decreased the pruritus response induced by histamine, C48/80, chloroquine and BAM8-22 within 30 min. MJS reduced scratching bouts and lessened the wiping reaction of mice under TRPV4 activation by GSK101 (10 µg/5 μl). MJS inhibited scratching behavior in acetone–ether–water (AEW)-treated mice within 60 min. An H1 receptor antagonist—chlorpheniramine (CLP, 400 mg/kg)—and a TRPV4 antagonist—HC067047 (250 ng/kg), exhibited similar effects to those of MJS. Moreover, MJS ameliorated dry skin itch-associated cutaneous barrier disruption in mice. MJS did not inhibit the expression of TRPV4 in the dorsal root ganglion neurons at L2–L3 in AEW mice. These results indicate that the analgesic and anti-pruritic effects of MJS in acute and chronic pain and itching, as well as itching caused by TRPV4 activation, could be attributed to the TRPV4 pathway modulation.